Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8273441 | 1.00 | ADAM17 (0.54) | ADAM17MEN1KMT2AUSP2GAA | |
| SCHEMBL8217820 | 0.88 | ADAM17 (0.70) | ADAM17NAMPT | |
| SCHEMBL8217827 | 0.88 | ADAM17 (0.70) | ADAM17NAMPT | |
| SCHEMBL8275600 | 0.87 | ADAM17 (0.45) | ADAM17MEN1KMT2ANAMPTADAM10 | |
| SCHEMBL8273449 | 0.85 | ADAM17 (0.47) | ADAM17MEN1KMT2AUSP2GAA | |
| SCHEMBL8275634 | 0.82 | ADAM17 (0.79) | ADAM17ADAM10MMP12MMP13 | |
| SCHEMBL8274428 | 0.79 | ADAM17 (0.49) | ADAM17GAADPP7DPP4 | |
| SCHEMBL8273743 | 0.75 | ADAM17 (0.46) | ADAM17MEN1KMT2ANAMPTADAM10 | |
| SCHEMBL8274406 | 0.75 | ADAM17 (0.49) | ADAM17MEN1KMT2AUSP2GAA | |
| SCHEMBL8276118 | 0.74 | ADAM17 (0.43) | ADAM17MEN1KMT2AGAANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |